Products found to contain undeclared medicines
|
| |
| The United States: WS Global issues nationwide recall of Himalayan Pain Relief Tea due to the presence of hidden drug ingredients diclofenac and dexamethasone |
| |
The US Food and Drug Administration (FDA) announces that WS Global Inc. is voluntarily recalling all lots of Himalayan Pain Relief Tea, tea packets to the consumer level. The product has been found to contain undeclared drugs diclofenac and dexamethasone.
Diclofenac is a non-steroidal anti-inflammatory drug (commonly referred to as NSAIDs). NSAIDs may cause increased risk of cardiovascular events, such as heart attack and stroke, as well as serious gastrointestinal damage, including bleeding, ulceration, and fatal perforation of the stomach and intestines. This hidden drug ingredient may also interact with other medications and significantly increase the risk of adverse events, particularly when consumers use multiple NSAID-containing products.
Dexamethasone is a corticosteroid commonly used to treat inflammatory conditions. Corticosteroid use can impair a person’s ability to fight infections and can cause high blood sugar levels, muscle injuries and psychiatric problems. When corticosteroids are taken for a prolonged period, or at high doses, they can suppress the adrenal gland. Only licensed health care professionals can evaluate patients for the risk or existence of adrenal suppression. In addition, the undeclared dexamethasone in Himalayan Pain Relief Tea may cause serious side effects when combined with other medications.
To date, WS Global Inc. has not received any reports of adverse events related to this recall.
Consumers taking Himalayan Pain Relief Tea should immediately consult their health care professional to safely discontinue use of this product. The risks of withdrawal from corticosteroids should be assessed by a health care professional. Abrupt discontinuation can cause withdrawal symptoms.
Please refer to the following website in FDA for details:
http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/ws-global-issues-nationwide-recall-himalayan-pain-relief-tea-due-presence-hidden-drug-ingredients
In Hong Kong, the above product is not a registered pharmaceutical product. Related news was previously issued by FDA, and was posted on the Drug Office website on 20 Nov 2023.
Ends/Thursday, Dec 14, 2023
Issued at HKT 15:30
|
| |
|
